Exchange: NASDAQ·Updated 07:30 PM EST

DYN News

News
all
press releases
Dyne Therapeutics (NASDAQ:DYN) Shares Cross Below 50 Day Moving Average Following Insider Selling
Dyne Therapeutics (NASDAQ:DYN) Stock Price Breaks Below Fifty Day Moving Average Following Insider Selling...
MarketBeat
Dyne Therapeutics (NASDAQ:DYN) Shares Cross Below 50 Day Moving Average Following Insider Selling
Dyne Therapeutics (NASDAQ:DYN) Stock Price Breaks Below Fifty Day Moving Average Following Insider Selling...
MarketBeat
More News
Dyne Therapeutics, Inc. (NASDAQ:DYN - Get Free Report) CFO Erick Lucera sold 1,991 shares of the company's stock in a transaction dated Friday, November 13th. The stock was sold at an average price of $16.82, for a total transaction of $33,488.62. Following the completion of the transaction, the...
MarketBeat
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which me...
Nasdaq News: Markets
RBC Capital highlighted differences in how Novartis’ and Dyne’s drugs target transferrin protein, their payloads, and their clinical trial designs.
Stocktwits
The company said on Tuesday that its experimental drug del-desiran failed in a late-stage trial.
Stocktwits
Dyne Therapeutics stock sinks on Novartis' failed Phase 3 myotonic dystrophy study, even as Dyne prepares new trial data presentations.read more...
Benzinga
Sarepta falls nearly 10% in a week after Dyne Therapeutics wins FDA priority review for a rival DMD therapy that could challenge Exondys 51 if approved.
Zacks
Dyne Therapeutics stock fell after hours after pricing an upsized $375M public offering of common stock.read more...
Benzinga
Dyne Therapeutics announced plans to raise $300 million through a public stock offering on Tuesday.
Stocktwits
Citi reiterated a ‘Sell’ rating on SRPT, citing the expected rise in competition within the Duchenne muscular dystrophy (DMD) exon-skipping market.
Stocktwits

Advertisement|Remove ads.